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ABSTRACT: DNA methylation profiling has proven to be a powerful analytical tool, which can accurately identify the tissue of origin of a
wide range of benign and malignant neoplasms. Using microarray-based profiling and supervised machine learning algorithms, we and
other groups have recently unraveled DNA methylation signatures capable of aiding the histomolecular diagnosis of different tumor types.
We have explored the methylomes of metastatic brain tumors from patients with lung cancer, breast cancer, and cutaneous melanoma and
primary brain neoplasms to build epigenetic classifiers. Our brain metastasis methylation (BrainMETH) classifier has the ability to determine
the type of brain tumor, the origin of the metastases, and the clinical-therapeutic subtype for patients with breast cancer brain metastases. To
facilitate the translation of these epigenetic classifiers into clinical practice, we selected and validated the most informative genomic regions
utilizing quantitative methylation-specific polymerase chain reaction (qMSP). We believe that the refinement, expansion, integration, and
clinical validation of BrainMETH and other recently developed epigenetic classifiers will significantly contribute to the development of more
comprehensive and accurate systems for the personalized management of patients with brain metastases.
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Brain metastasis (BM) is a deadly complication that occurs in
an estimated 10% to 20% of all cancer patients, most frequently
originating from lung cancer, breast cancer, and cutaneous melanoma.1 Often, it can be the initial presenting manifestation in
patients with otherwise previously undiagnosed advanced stage
cancer. Due to the dismal prognosis of this clinical complication,
efficient and effective diagnosis and treatment are crucial.
Valuable information used to guide therapeutic approaches
can be derived from the status of the systemic disease, patient’s
performance status, number, size and location of BM, and
direct BM profiling, which can provide actionable alterations
and aid in both diagnosis and prognosis of the disease.
Exemplifying the importance of profiling of BM specimens, a
recent study found that 53% of BMs have clinically informative molecular alterations not detected in the matched primary
tumor.2 Furthermore, in some cases, the accurate diagnosis of
BM may be challenging for pathologists and clinicians, especially when the availability of BM surgical specimens is limited
and/or when a BM is poorly differentiated. These challenges
highlight the need to profile BM tissue directly to properly
determine an accurate therapeutic approach.
In recent years, innovative studies have demonstrated the
ability of DNA methylation profiling to aid in the diagnosis of
cancers from unknown primary sites,3 primary central nervous
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system (CNS) tumors,4–6 and other primary neoplasms.7–9
Given the potential clinical utility of DNA methylation profiling and leveraging on the findings of our seminal studies,10–12
we recently aimed to complement these disease-specific epigenetic classifiers by first generating unique DNA methylation
signatures of the most frequent types of metastatic brain tumors,
followed by developing an efficient system to aid in the diagnosis of challenging cases by using a relatively small portion of
BM tissue.13 With this goal in mind, we focused on identifying
informative combinations of genomic regions whose DNA
methylation level could predict the type of brain tumor, the tissue of origin, and therapeutically relevant subtypes of metastatic
brain tumors.13 To generate high-quality genome-wide DNA
methylomes that could be easily compared with data from other
studies, we analyzed genomic DNA derived from micro-dissected formalin-fixed paraffin-embedded (FFPE) BM specimens with the Infinium HumanMethylation 450K (HM450K)
microarray.14 In our study, we included specimens from lung
cancer brain metastases (LCBMs), breast cancer brain metastases (BCBMs), and melanoma brain metastases (MBMs), the
three most frequent types of BM. In addition, we included BM
specimens from patients with uncertain or incomplete histopathology diagnosis. We further integrated publicly available
large-scale data from a variety of brain and extracranial primary
tumors and employed machine learning algorithms to build
robust BM classifiers.
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Figure 1. Application of the BrainMETH classifiers for the stratification of multiple brain tumors: (A) Distances between primary brain tumors
(glioblastoma; purple branches; n = 60) and brain metastases (BMs; red branches; n = 94) using the DNA methylation levels of genomic regions included in
the BrainMETH classifier A. (B) Distances between metastatic brain tumors from patients with primary lung cancer (LCBM; blue branches; n = 22), breast
cancer (BCBM; pink branches; n = 28), and melanoma (MBM; brown branches; n = 44) using the DNA methylation levels of genomic regions included in the
BrainMETH classifier B. (C) Distances between brain metastases from different breast cancer therapeutic subtypes including hormone receptor
(HR)-positive/HER2-negative BCBMs (green branches; n = 13), HER2-positive BCBMs (blue branches, n = 13), and HR-/HER2- (a.k.a. triple-negative
breast cancer) BCBM (red branches; n = 5) using the DNA methylation levels of genomic regions included in the BrainMETH classifier C. The phenetic
trees were generated using the Pearson’s Correlation as a distance metric, with average linkage as clustering approach in the FigTree, version 1.4.3, tool
with radial tree layout.

Our study resulted in a three-step brain metastasis DNA
methylation (BrainMETH) classification system capable of
distinguishing (1) BM from primary brain tumors
(BrainMETH classifier A), (2) the tissue of origin of the
BM specimen (BrainMETH classifier B), and (3) the therapeutically relevant subtype of BM specimens in breast cancer
patients (i.e. hormone receptor–positive/HER2-negative,
HER2-positive and triple-negative breast cancer, BrainMETH
classifier C; Figure 1).13 These classifiers demonstrated an
excellent ability to determine the origin and therapeutic subtype of metastatic brain tissues, even for cases with unknown or
uncertain initial diagnosis, missing information, and patients
with synchronous or asynchronous brain lesions. To further the
translation of these findings into clinical practice, we selected
the most informative genomic regions and designed specific
targeted DNA methylation assays using quantitative methylation-specific polymerase chain reaction (qMSP). This costeffective approach showed excellent efficiency in accurately
diagnosing both primary and metastatic brain tumors of various origins.
To ensure the reproducibility of these findings and increase
the utility of the data generated from this study, we deposited
the raw methylation data to the National Center for
Biotechnology Information (NCBI)’s Gene Expression
Omnibus (GEO) repository (GSE108576 and GSE44661)
and provided all the relevant clinical information for patients
included in the study as part of a separate article.14 This
resource supports interoperability and wider use by the bioscience community by providing a manually curated data set in
the Investigation-Study-Assay (ISA) framework that includes
the clinical-demographic information for all the patients linked
to the respective raw DNA methylation data (.idat) files. In
addition to the standardization for downstream data analysis
provided by the ISA framework, we believe that this resource
will not only allow for the replication of each step of our study

but will also facilitate the translation of these data into additional practical histomolecular applications.14
Additional expansion of the BrainMETH classifier would
involve the evaluation of BM from less frequent origins, such
as renal or colorectal carcinoma that were not covered in our
studies. As recently demonstrated for glioblastoma, a potential
limitation of these analyses is the presence of intra-tumor
DNA methylation heterogeneity.15 Perhaps this, as well as
other disease-specific features, should be considered in future
work to improve and expand the applicability of DNA methylation–based diagnostic signatures for clinical use.
The acquisition of samples for accurate diagnosis can be
challenging in some patients with brain neoplasms due to several factors, such as anatomical location or extensive metastatic
disease (making patients poor candidates for neurosurgery).
Establishing a minimally invasive approach to identify therapeutic targets, diagnose, classify, and potentially follow-up
BM lesions will significantly impact the management of
patients with brain neoplasms. Recent next-generation
sequencing-based approaches have shown that BM can be
profiled using cell-free DNA (cfDNA) extracted from cerebrospinal fluid (CSF) without the need for surgical intervention.16,17 We speculate that the adaptation of the BrainMETH
classifier and CNS tumor DNA methylation classifiers to
cfDNA derived from pre-surgical CSF specimens may significantly impact patient management, leading to a reduction
of invasiveness, especially for those patients with uncertain
diagnosis and inoperable brain tumors.
Given the impactful clinical applications of DNA methylation analysis, we believe that the clinical and epigenetic data
generated in our study can be easily adapted to expand the
applications of the BrainMETH classifier and to identify new
epigenetic signatures involved in the BM etiology. Specifically,
the adaptation and validation of these epigenetic classifiers to
streamlined polymerase chain reaction (PCR)-based assays
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may allow a wide range of laboratories to assay patient-derived
tumors in a cost-effective manner.
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